Cardiovascular Risk Reduction in T2DM: Applying Trial Data in Cardiology Practice
| Overview / Abstract: |
Cardiovascular disease (CVD) is a leading cause of death in patients with type 2 diabetes mellitus (T2DM). The presence of diabetes also markedly increases the risk of 1-year adverse clinical outcomes (hospitalizations, mortality) in outpatients with heart failure. Multiple clinical trials have been undertaken to address critical issues in the management of CVD and T2DM. Trial findings have shown that the use of newer antihyperglycemic agents can reduce the rate of major cardiovascular events, including heart failure. Cardiovascular Risk Reduction in T2DM: Applying Trial Data in Cardiology Practice will explore the burden of CVD in patients with T2DM, and outline the results from cardiovascular outcomes trials exploring the benefits and risks of antihyperglycemic agents in reducing CVD in patients with T2DM. |
|
Expiration |
May 24, 2020 |
|
Discipline(s) |
Physician CME |
|
Format |
Online, Webinar / Webcast / Video |
|
Credits / Hours |
ACCME - 1.00 AMA PRA Category 1 Credit |
|
Accreditation |
Jointly provided by USF Health and Rockpointe |
|
Presenters / Authors / Faculty |
Prakash Deedwania, MD, FACC, FAHA, FACP, FASH, FHFSA, FESC Michael E. Nassif, MD |
|
Sponsors / Supporters / Grant Providers |
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.; Lilly USA, LLC; and Novo Nordisk, Inc. |
|
Keywords / Search Terms |
Rockpointe CVD, T2DM, Cardiovascular disease, Type 2 diabetes mellitus, CME, Free CME, Continuing Medical Education, CME Webcourse, Primary Care, Primary Care Provider, On-Demand CME, Diabetes, Cardiology Free CE CME |
|